Cagri-Reta 10mg
Cagrilintide / Retatrutide
CAS: 2381089-29-0 / 2381089-83-2
Cagri-Reta 10mg blend — Cagrilintide (amylin/AMY receptor agonist) combined with Retatrutide (GLP-1R/GIPR/GcgR triple agonist). Targets four independent appetite/metabolic receptor systems simultaneously. Research-grade pre-mixed vial. 98.5% HPLC purity.
Specifications
For laboratory research use only. Not for human consumption.
Mechanism of Action
Four-receptor co-stimulation: AMY1/AMY3 (brainstem satiety via cagrilintide) + GLP-1R (hypothalamic appetite) + GIPR (incretin potentiation) + GcgR (thermogenesis and energy expenditure) via retatrutide.
Research FAQ
What is the rationale for combining cagrilintide with retatrutide?
Cagrilintide adds amylin receptor (AMY1/AMY3) signaling to retatrutide's triple GLP axis, engaging a fourth independent appetite suppression circuit for potentially additive metabolic effects.
